AU2017225076C1 — Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
Assigned to Alnylam Pharmaceuticals Inc · Expires 2025-02-27 · 1y expired
What this patent protects
The present invention provides RNAi agents, e.g., double 5 stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases. 9403909_1 (GHMatters) P96961.AU.1 21/08/17
USPTO Abstract
The present invention provides RNAi agents, e.g., double 5 stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases. 9403909_1 (GHMatters) P96961.AU.1 21/08/17
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.